Dr.
Brown graduated from Washington University in St. Louis,
Missouri with a Bachelor of Arts degree in biology. He
attended medical school at the University of Michigan,
and completed his post-graduate residency training in
Radiation Oncology at Massachusetts General Hospital
in Boston. Dr. Brown was Chief Resident in Radiation
Oncology from July 2002 through June 2003. He has received
the National Medical Association Fellowship Award, the
National Center on Minority Health and Health Disparities
Loan Repayment Award, and was a member of the Alpha Omega
Alpha Medical Honor Society. He completed research in
breast cancer incidence and age distribution in minorities
and he has done work with BOLD MR Imaging which allows
assessment of reductions in tumor oxygen supply. He has
also has published several articles on various cancer
topics.
Dr. Brown is trained in conformal 3-D radiation therapy,
intensity modulated radiation therapy (IMRT), stereotactic
radiosurgery (SRS), proton irradiation, high dose rate
brachytherapy, and permanent Brachytherapy (seed implants).
He has a particular interest in central nervous system,
gastrointestinal, genitourinary, lung, and breast malignancies.
Dr. Brown participated in the Boston Advisory Committee
for the Prostate Health Education Network, and is a former
board member of the Diversity Committee at Massachusetts
General Hospital. He was also a member of the American
Cancer Society's Early Detection and Prevention Committees
while practicing in Chicago. He was recently involved in
production of a prostate cancer awareness video for the
American Cancer Society. He is a member of the American
Society of Therapeutic Radiation Oncology and the American
Society of Clinical Oncology. He spends his leisure time
increasing cancer awareness in urban areas, community service
related activities, and engaging in a variety of sports.
When asked why
he chose Radiation Oncology, he states, “Radiation
Oncology is both a challenging and dynamic field, two aspects
that I seek in a career. It offers cutting edge technology
that will allow improvements in tumor control and decrease
side effects commonly associated with cancer treatment.
Ultimately, this translates into longer survival and improved
quality of life for cancer patients.”
